IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Ranbaxy’s Controversial India Plant Gets Australian, U.K. Regulatory Approvals

2:06 AM MDT | March 23, 2009 | Deepti Ramesh

Ranbaxy Laboratories (Gurgaon, India) says that the Medicines and Healthcare products Regulatory Agency (MHRA; London) of the U.K., and the Therapeutic Goods Administration (TGA; Canberra), Australia’s drug regulatory body, have issued good manufacturing practice (GMP) certificates for Ranbaxy’s Paonta Sahib, India manufacturing facility, following a joint audit conducted last October. Ranbaxy says that the MHRA approval will cover product filings for the U.K. and also apply to product filings for the entire European Union. The U.S. FDA said last...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa